within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DD62_CefoperazoneAndBetaLactamaseInhibitor;
model CefoperazoneAndBetaLactamaseInhibitor 
   extends Pharmacolibrary.Drugs.ATC.J.J01DD62;

  annotation(Documentation(
    info ="<html><body><p>Cefoperazone is a third-generation cephalosporin antibiotic, often combined with beta-lactamase inhibitors (such as sulbactam or tazobactam) to broaden its spectrum against beta-lactamase-producing gram-negative bacteria. This combination is used for the treatment of moderate to severe infections including respiratory tract, urinary tract, intra-abdominal infections, and sepsis. It is approved and used clinically, mainly in hospital settings.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for typical adult patients based on available data for cefoperazone with sulbactam. No direct PK publication found for the exact combination ATC J01DD62; parameters estimated from available literature on cefoperazone combinations.</p><h4>References</h4><ol><li><p>Johnson, CA, et al., &amp; Craig, WA (1988). Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysis. <i>Antimicrobial agents and chemotherapy</i> 32(1) 51–56. DOI:<a href=&quot;https://doi.org/10.1128/AAC.32.1.51&quot;>10.1128/AAC.32.1.51</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3348613/&quot;>https://pubmed.ncbi.nlm.nih.gov/3348613</a></p></li><li><p>Muder, RR, et al., &amp; Venkataramanan, R (2002). Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients. <i>Journal of clinical pharmacology</i> 42(6) 644–650. DOI:<a href=&quot;https://doi.org/10.1177/00970002042006006&quot;>10.1177/00970002042006006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12043952/&quot;>https://pubmed.ncbi.nlm.nih.gov/12043952</a></p></li><li><p>Danziger, LH, et al., &amp; Rodvold, KA (1994). Steady-state pharmacokinetics of cefoperazone and sulbactam in patients with acute appendicitis. <i>The Annals of pharmacotherapy</i> 28(6) 703–707. DOI:<a href=&quot;https://doi.org/10.1177/106002809402800602&quot;>10.1177/106002809402800602</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7919553/&quot;>https://pubmed.ncbi.nlm.nih.gov/7919553</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end CefoperazoneAndBetaLactamaseInhibitor;
